EPS: As of FY2025 Q1, the actual value is USD -0.29.EBIT: As of FY2025 Q1, the actual value is USD -709.56 K.<h3>Operational Metrics</h3><ul><li>Net Loss: The company reported a net loss of $709,555 for the three months ended March 31, 2025, compared to a net loss of $971,322 for the same period in 2024.</li><li>Research and Development Costs: $91,457 for the three months ended March 31, 2025, down from $119,064 for the same period in 2024.</li><li>General and Administrative Costs: $615,483 for the three months ended March 31, 2025, down from $847,815 for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: -$568,483 for the three months ended March 31, 2025, compared to -$789,225 for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: $914,228 for the three months ended March 31, 2025, with no financing activities reported for the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Stock-Based Compensation: The company recorded stock-based compensation costs of $99,738 for the three months ended March 31, 2025, compared to $102,927 for the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company is focusing on the clinical development of LB-100, a protein phosphatase inhibitor, which has shown clinical anti-cancer activity. The company estimates that existing cash resources will fund operations through September 30, 2025, but additional capital will be needed by mid-2025 to continue operations.</li><li>Non-Core Business: The company is undertaking measures to regain compliance with Nasdaq’s continued listing requirements by July 3, 2025, but there is no assurance of success.</li></ul>

LIXTE BIOTECHNOLOGY HOLDINGS INC C/WTS 30/11/2025 (TO PUR COM) | 10-Q: FY2025 Q1 EPS: USD -0.29